Why successful chemical companies are digitalizing their R&D, sales and marketing

Webinar on Chemical Science and Chemical Engineering Which is happening during May 4-5, 2022. It provides a platform for researches to present their ideas, research results and development activities about all aspects of Chemical Science and Chemical Engineering.

Have you ever wondered what it takes for a company to stay in business for more than a century? For The Dow Chemical Company, the answer lies in continual global innovation and investment in R&D. When problems arise, Dow finds solutions.

In this webinar, we will explore best practice approaches for seamless handover at critical junctures en route to commercial manufacturing of small molecule drugs. One of the biggest challenges in today's small molecule drug development are the different requirements on quality and supply chain going from exploratory research to commercial manufacturing. A key risk to consider is the over- and/or underengineering of chemical specialties for drug synthesis leading to higher total cost of ownership.

Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) discussed screen design, target bias, and hit-prioritization strategies to identify those entities with the greatest opportunity to be developed into the next new antibiotic.